multi-valent pneumococcal conjugate vaccine
Vaccineexperimental
Clinical trial activity
74 trials · 61 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
54
Phase 3
44
Phase 4
12
Earliest trial started Feb 1, 2003 (NCT00148824)
Timeline
Indications
Approved for
Studied for
- Aging · Early Phase 1
- Antibody Formation · Phase 3
- Breast Neoplasms · Phase 2
- Colitis, Ulcerative · Phase 4
- Communicable Diseases · Phase 2
- Crohn Disease · Phase 4
- Diabetes Mellitus, Type 1 · Phase 4
- Diphtheria · Phase 2
- Diphtheria-Tetanus-acellular Pertussis Vaccines · Phase 2
- Drugs, Investigational · Phase 2
- Haemophilus influenzae type b · Phase 2
- Healthy Volunteers · Phase 3
- Hepatitis B · Phase 2
- HIV-Associated Lipodystrophy Syndrome · Early Phase 1
- HIV Infections · Phase 3
- Immunization · Phase 4
- Inflammatory Bowel Diseases · Phase 4
- Influenza, Human · Phase 4
- Kidney Failure, Chronic · Phase 4
- Lung Diseases · Phase 4
- Lung Neoplasms · Phase 2
- Meningitis · Phase 3
- Meningitis, Meningococcal · Phase 3
- Meningococcal Infections · Phase 3
- Multiple Sclerosis, Relapsing-Remitting · Phase 3
- Otitis Media · Phase 3
- Otitis Media with Effusion · Phase 3
- Pertussis Vaccine · Phase 2
- Pneumococcal Infections · Phase 4
- Pneumococcal Vaccines · Phase 4
- Pneumonia · Phase 4
- Pneumonia, Pneumococcal · Phase 4
- Pneumonia, Staphylococcal · Phase 3
- Poliomyelitis · Phase 2
- Premature Birth · Phase 4
- Prostatic Neoplasms · Phase 2
- Rotavirus Infections · Phase 3
- Safety · Phase 4
- Streptococcal Infections · Phase 3
- Streptococcus pneumoniae · Phase 4
- Tetanus · Phase 2
- Tympanic Membrane Perforation · Phase 3
- Vaccines · Phase 3
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 10 valent pneumococcal conjugate vaccine
- 10-valent pneumococcal conjugate vaccine
- 10-valent pneumococcal conjugate vaccine
- 13-valent pneumoccocal conjugate vaccine
- 13-valent pneumococcal conjugate vaccine
- 23-valent pneumococcal conjugate vaccine
- multivalent pneumococcal conjugate vaccine
- pcv10
- pcv10
- pcv-10
- ten-valent pcv
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03550313 | Phase 2 | Jun 1, 2018 | Pfizer |
| NCT03467984 | Phase 2 | Apr 30, 2018 | LG |
| NCT03313050 | Phase 1 | Oct 12, 2017 | Pfizer |
| NCT02943902 | Phase 3 | Jan 9, 2017 | University of London, University of the Witwatersrand |
| NCT02955160 | Phase 1 | Nov 1, 2016 | Pfizer |
| NCT02961231 | Phase 4 | Nov 1, 2016 | Government of Vietnam, Murdoch University, University of London, University of Nagasaki |
| NCT02736240 | Phase 3 | Apr 1, 2016 | Walvax Biotechnology Co., Ltd. |
| NCT02628886 | Phase 3 | Mar 1, 2016 | Medical Research Council, The Gambia, University of Western Ontario, World Health Organization |
| NCT02717494 | Phase 2 | Mar 1, 2016 | National Institutes of Health (NIH), University of Colorado, Denver, Westat |
| NCT02545868 | Phase 3 | Oct 27, 2015 | Roche |
| NCT03039491 | Early Phase 1 (Phase 1) | Sep 1, 2015 | Medical University of South Carolina, University of South Carolina |
| NCT02482636 | Phase 2 | Aug 1, 2015 | Public Health England, University of London, University of Oxford |
| NCT02385513 | Phase 4 | May 1, 2015 | GAVI - The Vaccine Alliance, Patan Academy of Health Sciences, University of Oxford |
| NCT02034877 | Phase 4 | Aug 1, 2014 | Pfizer |
| NCT01908283 | Phase 4 | Mar 1, 2014 | Foundation for liver and gut studies, Schweizerische Morbus Crohnund Colitis ulcerosa Vereinigung, Swiss IBD Cohort Study, University of Geneva |
| NCT01964716 | Phase 3 | Jan 1, 2014 | Pfizer |
| NCT02062281 | Phase 4 | Nov 1, 2013 | Chengdu Institute of Biological Products Co.,Ltd., China National Biotec Group Co., Ltd, Government of China |
| NCT01953510 | Phase 2/Phase 3 (Phase 3) | Sep 30, 2013 | GlaxoSmithKline, Institut Pasteur, Menzies School of Health Research, Murdoch University, National Health and Medical Research Council, Australia |
| NCT01939522 | Phase 4 | Aug 1, 2013 | University of Oxford |
| NCT02558751 | Early Phase 1 (Phase 1) | Jul 1, 2013 | National Institute on Aging (NIA), University of Toledo |
Showing 20 of 74 trials
Page 1 / 4
Organizations
Research & Development (61)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 42 | 41 | 4 | 2004 |
| Wyeth | For profit | 14 | 0 | 2 | 2003 |
| GlaxoSmithKline | For profit | 7 | 5 | 3 | 2006 |
| University of Oxford | Academic/Hospital | 5 | 4 | 3 | 2010 |
| Menzies School of Health Research | Academic/Hospital | 3 | 2 | 1 | 2006 |
| Novartis | For profit | 3 | 3 | 2 | 2007 |
| University of London | Academic/Hospital | 3 | 0 | 3 | 2015 |
| Murdoch University | Academic/Hospital | 2 | 0 | 2 | 2013 |
| National Health and Medical Research Council, Australia | Government | 2 | 0 | 1 | 2006 |
| University of Colorado, Denver | Academic/Hospital | 2 | 0 | 2 | 2010 |
| University of Melbourne | Academic/Hospital | 2 | 1 | 1 | 2006 |
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Centers for Disease Control and Prevention (CDC) | Government | 1 | 1 | 1 | 2004 |
| Chengdu Institute of Biological Products Co.,Ltd. | Government | 1 | 0 | 1 | 2013 |
| China National Biotec Group Co., Ltd | For profit | 1 | 0 | 1 | 2013 |
| Chung-Ang University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Ewha Womans University | Academic/Hospital | 1 | 0 | 1 | 2011 |
61 organizations
Page 1 / 4